Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
about
In vitro cytotoxicity and mitochondrial toxicity of tenofovir alone and in combination with other antiretrovirals in human renal proximal tubule cellsA Review of Management of Inflammation in the HIV PopulationFactors associated with paradoxical immune response to antiretroviral therapy in HIV infected patients: a case control study.Tenofovir disoproxil fumarate for the treatment of HIV infection.Intracellular nucleotide levels during coadministration of tenofovir disoproxil fumarate and didanosine in HIV-1-infected patients.Role of the Pharmacist in Caring for Patients with HIV/AIDS: Clinical Practice Guidelines.Current status of antiretroviral therapy.Tenofovir disoproxil fumarate-emtricitabine coformulation for once-daily dual NRTI backbone.Review of tenofovir-emtricitabine.Tenofovir-induced kidney injury.Evaluation of the pathogenesis of decreasing CD4(+) T cell counts in human immunodeficiency virus type 1-infected patients receiving successfully suppressive antiretroviral therapy.Drug interactions in the management of HIV infection: an update.Pilot pharmacokinetic study of human immunodeficiency virus-infected patients receiving tenofovir disoproxil fumarate (TDF): investigation of systemic and intracellular interactions between TDF and abacavir, lamivudine, or lopinavir-ritonavir.Renal toxicity associated with tenofovir use.Conserved T cell and natural killer cell function in treatment-experienced adults receiving tenofovir plus didanosine as nucleoside reverse transcription inhibitor backbone.CD4+ cell count decline despite HIV suppression: a probable didanosine-valganciclovir interaction.Prevalence of discordant immunologic and virologic responses in patients with AIDS under antiretroviral therapy in a specialized care center in Brazil.Role of tenofovir in the treatment of chronic HBV infection
P2860
Q24674939-981328E7-A8C5-4E6F-BD00-061085429F85Q28078962-B5576CBF-5F56-4400-8D17-9CD53844BB5EQ34065045-7D232746-F3A7-4449-81E7-4E83A68EA2CEQ34569309-9FC0DB78-90DD-4C42-8591-C4194A5E38B6Q34737466-24B3B203-814B-4C75-9A88-6EFA01797345Q35898538-F75AF56B-9A70-421B-8FB6-3D6D3FB2A109Q36548703-3038882A-79F1-47F6-BCB1-25160DA79E2DQ36607380-471F82C8-1816-48C5-9445-A052F7A94B17Q36663686-6F3D7424-E8E9-4DC3-A5A6-1861BF8E86A7Q36762441-01F8C9BC-1C8A-418C-9C00-F1330067B7DDQ36783609-6C057964-E6AD-4292-BF15-2BB9DEF485CAQ37000733-89FA05D2-AE5F-47DA-97B3-B585C23B35FAQ37190767-FFF1385E-A176-443C-8143-A5BAE5D96085Q37729160-5A33ADAF-EDCC-417A-9241-49F8DD485C25Q43279654-EF18CC77-47F2-4A17-93D3-AB413020DF41Q43646614-1CF090AA-C5CF-41BF-A1A7-7E1999279011Q44120477-6CCC7FDE-9B47-4C3B-97CF-19F6E0AF9648Q58098975-9647AF09-F638-4F6E-B0EC-5694D4BB5E77
P2860
Paradoxical CD4+ T-cell decline in HIV-infected patients with complete virus suppression taking tenofovir and didanosine.
description
2005 nî lūn-bûn
@nan
2005年の論文
@ja
2005年学术文章
@wuu
2005年学术文章
@zh
2005年学术文章
@zh-cn
2005年学术文章
@zh-hans
2005年学术文章
@zh-my
2005年学术文章
@zh-sg
2005年學術文章
@yue
2005年學術文章
@zh-hant
name
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@en
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@nl
type
label
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@en
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@nl
prefLabel
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@en
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@nl
P2093
P50
P1433
P1476
Paradoxical CD4+ T-cell declin ...... king tenofovir and didanosine.
@en
P2093
Ana Barrios
Ana Rendón
David Cooper
Eugenia Negredo
Francisco Blanco
Ivana Maida
Jesús Santos
Juan Gonzalez-Lahoz
Luz Martín-Carbonero
Maria Antonia Sambeat
P304
P356
10.1097/01.AIDS.0000163933.14649.93
P407
P577
2005-03-01T00:00:00Z